Harvard Pilgrim Health Care’s health insurance plans in Maine reversed course and will now cover Biktarvy along with four other HIV meds. The change came about after health advocates led by the HIV+Hepatitis Policy Institute filed a discrimination complaint with the Maine Bureau of Insurance, which investigated the matter.

HIV+Hep filed similar complaints against Harvard Pilgrim plans in Rhode Island and New Hampshire.

Biktarvy is the most commonly prescribed HIV therapy today; indeed, more than 49% of people on HIV treatment take this med, according to a statement by HIV+Hep. The single-tablet, once-a-day regimen is manufactured by Gilead Sciences and was approved by the Food and Drug Administration in 2018.

National HIV treatment guidelines recommend four preferred regimens as initial therapy and four alternative therapies for specific situations. It is standard practice for health insurance plans to cover these treatments; failure to do so is considered discriminatory.

Harvard Pilgrim Health Care (also known as Point32 Health) in Maine will now cover those regimens. Harvard Pilgrim is one of two options for people enrolled in the Maine AIDS Drug Assistance Program.

HIV+Hep notes that Rhode Island health insurance officials earlier this month rejected the advocates’ discrimination claim against Harvard Pilgrim.

“While this action is certainly welcome, the fact remains that Harvard Pilgrim removed lifesaving HIV drugs from its coverage formulary, disrupted the treatment of people living with HIV and violated the nondiscrimination protections [of the Affordable Care Act (ACA), or Obamacare],” said Carl Schmid, executive director of the HIV+Hep. “This demonstrates the need for greater oversight of the health insurance industry and enforcement of the safeguards in place to protect patients against the abuse of insurers.”

The Maine Bureau of Insurance noted that as a result of its investigation, all health insurance plans available on CoverMe.gov (the website for Maine’s health insurance marketplace) will cover Biktarvy on their 2025 formulary plans. “The Bureau of Insurance will make certain that people with HIV—or any other condition—are not unfairly discriminated against or forced to switch insurers to maintain their course of treatment,” said Bob Carey, the bureau’s superintendent of insurance, in a statement.

“I welcome action taken by Harvard Pilgrim to reverse its initial decision to exclude these drugs—a decision made after the Bureau of Insurance pushed for this change,” Carey added. “I also appreciate the work that health care advocates, in particular the HIV + Hepatitis Policy Institute, and health care providers played in bringing this matter to our attention.”